<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977818</url>
  </required_header>
  <id_info>
    <org_study_id>IB2017-METASARC</org_study_id>
    <nct_id>NCT03977818</nct_id>
  </id_info>
  <brief_title>METASARC: Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa</brief_title>
  <acronym>METASARC</acronym>
  <official_title>Patterns of Care and Outcomes of Patients With METAstatic Soft Tissue SARComa in a Real-life Setting: the METASARC Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Well-designed observational studies of individuals with rare tumors are needed to improve
      patient care, clinical investigations, and the education of healthcare professionals.

      The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with
      metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in
      the prospectively maintained database of the French Sarcoma Group will be analyzed with a
      focus on : number/frequency of systemic treatments per patient, number/frequency of patients
      with locoregional treatment of the metastasis, number/frequency of patients with
      chemotherapy, number/frequency of patients with an off-label drug.

      Outcome (time-to-next treatment [TNT] and overall survival [OS]) will be reported according
      to histological subtype, as well as the association between TNT and OS.

      Prognostic factors of OS will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 1990</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next treatment (TNT)</measure>
    <time_frame>2 years</time_frame>
    <description>time from the systemic treatment onset to the next treatment or death due to any cause, whichever came first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Interval between the diagnosis of metastatic disease or the first-line systemic therapy onset and the time of death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Sarcoma</condition>
  <condition>Metastases</condition>
  <condition>Chemotherapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>intervention as per recommendations</description>
    <other_name>surgery</other_name>
    <other_name>radiotherapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        advanced soft tissue sarcoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  advanced soft tissue sarcoma

          -  age &gt; 18

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Italiano, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié, Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carine Bellera, PhD</last_name>
    <email>c.bellera@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Mathoulin-Pélissier, MD/PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié, Comprehensive Cancer Center</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano, MD/PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard, Comprehensive Cancer Center</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Blay, MD/PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy, Comprehensive Cancer Center</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Le Cesne, MD/PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honoré C, Sargos P, Sunyach MP, Le Péchoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017 Apr 10;15(1):78. doi: 10.1186/s12916-017-0831-7.</citation>
    <PMID>28391775</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>outcome</keyword>
  <keyword>time to next treatment</keyword>
  <keyword>overall survival</keyword>
  <keyword>patterns of care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

